Pharma and Biotech Daily: Stay Informed on the Latest in the Healthcare World

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Medtronic is focusing on prediction as the next frontier in heart disease management, utilizing artificial intelligence to reduce false positives in its insertable cardiac monitors. The company's cardiovascular diagnostics and services business leader emphasizes the time-saving benefits for clinicians. Additionally, diabetes device firm Embecta is considering a sale two years after spinning out of BD, while Dexcom shares have plunged due to a lower sales outlook. The FDA has sent warning letters to Chinese syringe manufacturers, and the top five medtech deals in the first half of 2024 include Johnson & Johnson's takeover of Shockwave Medical. Roche Diagnostics' base business has grown 9 percent in the first half of 2024, and Tricares has raised $50 million to trial a tricuspid heart valve replacement system.Sanofi's bet on immunology is starting to pay off, with analysts noting that the pipeline of immune system therapies is underappreciated by investors. Pfizer's hemophilia gene therapy has shown positive results in late-stage studies, but questions remain about long-term potential. A startup led by former J&J executives, Third Arc Bio, raised $165 million for cancer and immune disease drugs. The US government declined to clear Bluebird Fertility Support for Zynteglo patients, and the GLP-1 drug race is heating up as pharma companies compete in the obesity market. The biopharma industry is evolving rapidly, with advancements in cell therapy and personalized cancer treatments.Steward Health System failed to attract qualified bidders during the first round of hospital sales in Ohio and Pennsylvania. Humana's CenterWell will open 23 primary care clinics in Walmart stores, while CMS is cracking down on ACA brokers to prevent unauthorized plan switching. AI is being used to power clinical trials and improve patient answer rates in healthcare organizations. The text also highlights stories from other publications, including the challenges faced by hospitals in non-Medicaid expansion states and the impact of Medicaid on insurers during the pandemic.Dexcom shares plunged due to a lower sales outlook, Abbott recalled Freestyle Libre 3 sensors for incorrect glucose readings, and a study found that AI's expert-level image analysis can be flawed. Edwards spent $1.2 billion on 2 heart device firms, Inspire Medical's COO is leaving for a CEO role at another company. Abbott stated that the sensor recall may affect less than 1% of users in the U.S. Researchers discovered that AI can generate expert-level image analysis with flawed reasoning. Edwards reported a slowdown in its core business, causing share prices to drop.Bristol Myers had a strong week of pharma earnings, with all five large pharmaceutical companies reporting raised profit or revenue guidance. Roche plans to move quickly with differentiated obesity drugs. Leqembi was voted down by European regulators, but Eisai plans to appeal. Two biotechs cut staff, while Abbvie weathers biosimilar threats. Sanofi's immunology pipeline is starting to pay off. The pharma industry is racing to develop GLP-1 drugs for obesity treatment.Gilead's $4.3 billion acquisition of Cymabay Therapeutics will face a significant test next month when the FDA decides on their autoimmune disease drug, Seladelpar. The treatment targets primary biliary cholangitis, a liver disease with no cure. Positive interim results have shown improvements in liver injury markers and reduced inflammation. Similarly, Citius Pharmaceuticals awaits an FDA decision on their rare blood cancer drug, Lymphir, with CEO Leonard Mazur personally investing $22.5 million in the company.The text discusses various marketing campaigns and initiatives, including Hyundai's shift to more emotional advertising for the Summer Olympics, Palo Alto Networks equipping Keanu Reeves with AI-powered weapons for a